HOME >> MEDICINE >> NEWS
New drug to treat enlarged prostate developed at UCL

Millions of men stand to benefit from a discovery by UCL scientists that could provide a breakthrough in the treatment of enlargement of the prostate (BPH). The UCL team has developed a new drug, Rho-kinase inhibitor that, in preliminary tests, has been found to treat the condition by both relaxing the prostate and stopping the growth of cells within it. Their findings are set out in the current issue of the Journal of Urology.

BPH affects approximately 85% of men over the age of 50 and causes frequent urination and irritation due to the obstruction of urine flow. The drugs currently available for treatment of BPH aim to either relax the prostrate or to reduce its size as two separate actions, and also have undesired hormonal effects. These effects, along with the need to take two separate treatments, often lead to problems of patient compliance. The discovery by the UCL scientists is novel in that this new drug can both relax the prostate and stop it from growing, with virtually no hormonal side effects.

Dr Selim Cellek, who led the investigation as a collaborative work between UCL's Wolfson Institute for Biomedical Research and its Institute of Urology and Nephrology, said: "We are very excited by this discovery, as it is a medical breakthrough which represents a major advance in treating a condition that affects such a large proportion of the population. We are still at the development stages and more research will be required before the new treatment becomes available. The next step will be to develop links with investors interested in developing this drug for the treatment of BPH.

"Research has shown that this type of compound can also be used to treat erectile dysfunction (impotence). The future for this line of research is therefore promising since men with an enlarged prostate often suffer from impotence. "

Malcolm Grant, UCL Provost, said: "The conversion of scientific results into new medicines is one of the main aims of th
'"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-207-679-9728
University College London
27-Nov-2003


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. Hormonal treatment improves survival in high-risk prostate cancer patients
3. Chronic pain treatments more effective when taken together, new study shows
4. Brain activity prior to treatment flags vulnerability to antidepressant side effects
5. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
6. OHSU scientists test medication to treat involuntary weight loss
7. Cultural and social factors influence prostate cancer treatment
8. Research offers hope of new treatments for liver damage
9. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
10. Risky surgery not always necessary to treat cervical disease
11. Stanford patient is first to test new treatment for peripheral arterial disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drug treat enlarged prostate developed UCL

(Date:3/30/2015)... This report studies the global pharmacovigilance and drug ... 2014 to 2019. This market is expected to ... to 2019. , Further Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=16831714 ... and drug safety software market has been classified ... namely, adverse event reporting software, drug safety audits ...
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... of its Top 10 Exotic Water Awards, with the top ... other winners are listed on the company’s website, along with ... Water’s website, exotic water, glacial water, spring water, mineral water ... Fiji water is one of the top exotic water ...
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition division ... Epax® Ultra and Core concentrates manufactured in the ... ensures the manufacturing process and all physical raw ... for Halal. , The new Halal certification ... advance its customer service to a global market ...
(Date:3/30/2015)... Slidezilla, an app from the makers of ... innovates the fun and simplicity of photo slideshows. The ... slideshows and then instantly share them across their Facebook, ... to create a slideshow app where users can share ... options to personalize them. You can choose your own ...
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a sleek ... and for reuse. Consumers simply twist the cup, turn it ... professionals, and basically anyone can now enjoy a non-alcoholic ... socially or pair with meals at work, home, or wherever ... and that means Napa Wine grapes undergo the traditional ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2
(Date:3/30/2015)... March 30, 2015   GlassesUSA , the online retailer ... $12.5 million in new financing led by Viola Private ... will further GlassesUSA,s aggressive business growth and accelerate their expansion ... online eyewear, both B2C and B2B. GlassesUSA was ... Eldad Rothman , and CTO Roy Yamner . ...
(Date:3/30/2015)... HA,AYIN, Israel , March 30, 2015 ... of Dr. Yuval Avni as the company,s ... partner at Giza VC, a leading early stage Israeli ... with clinical experience in general and vascular surgery.   ... company also announced today that Sherpa Innoventures is Beta-O2,s ...
(Date:3/30/2015)... Pharmaceuticals Corporation (NASDAQ: RXII ), a biotechnology ... primarily in the areas of dermatology and ophthalmology ... financial results for the fourth quarter and year ... update. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... a steady growth and evolution for RXi Pharmaceuticals," ...
Breaking Medicine Technology:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Beta-O2 Names Dr. Yuval Avni CEO 2Beta-O2 Names Dr. Yuval Avni CEO 3RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 2RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 3RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 4RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 5RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 6RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 7RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 8RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 9RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 10
Cached News: